MEDIGENE NA Share Price Swiss Exchange
Equities
OXMDGG
DE0005020903
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
05-21 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
05-21 | Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term | CI |
Sales 2024 * | 10.6M 11.5M 903M | Sales 2025 * | 6.95M 7.54M 592M | Capitalization | 35.38M 38.37M 3.01B |
---|---|---|---|---|---|
Net income 2024 * | -11M -11.93M -937M | Net income 2025 * | -17M -18.44M -1.45B | EV / Sales 2024 * | 4.94 x |
Net Debt 2024 * | 17M 18.44M 1.45B | Net Debt 2025 * | 14M 15.18M 1.19B | EV / Sales 2025 * | 7.1 x |
P/E ratio 2024 * |
-3.24
x | P/E ratio 2025 * |
-2.14
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.05% |
Latest transcript on MEDIGENE NA
Managers | Title | Age | Since |
---|---|---|---|
Selwyn Ho
CEO | Chief Executive Officer | 53 | 24/07/22 |
Dolores Schendel
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/14 |
Pamela Keck
IRC | Investor Relations Contact | - | 31/01/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 66 | 11/08/16 | |
Frank Mathias
BRD | Director/Board Member | 62 | 14/05/18 |
Anthony Man
BRD | Director/Board Member | 68 | 15/12/20 |
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- MDG1 Stock
- OXMDGG Stock